Skip Nav Destination
Issues
1 June 2014
-
Cover Image
Cover Image
Ductal carcinoma in situ (DCIS) is a nonmalignant lesion of the breast with the potential to progress to invasive ductal carcinoma (IDC). The disappearance and breakdown of the myoepithelial cell layer and basement membrane in DCIS have been identified as major events in the development of breast cancer. The inhibitory effects of the Gemini vitamin D analog BXL0124 on the transition from DCIS to IDC were investigated using the MCF10DCIS.com xenograft model in mice. To assess the effects of BXL0124 on the maintenance of myoepithelial cell layer and basement membrane in DCIS, co-immunofluorescence staining was carried out with a basement membrane marker, laminin 5, and a myoepithelial cell marker, smooth muscle actin (SMA), in DCIS tumors. The covermicrograph depicts the merged images of laminin 5 (shown in green), SMA (shown in red), or nuclei (blue). The present study demonstrates BXL0124 as a potential agent to inhibit the transition of DCIS to IDC by maintaining the integrity of the myoepithelial cell layer and the basement membrane. See the article by Wahler et al. (beginning on page 617) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Reviews
Research Articles
Author Choice
Chemoprevention of Esophageal Cancer with Black Raspberries, Their Component Anthocyanins, and a Major Anthocyanin Metabolite, Protocatechuic Acid
Daniel S. Peiffer; Noah P. Zimmerman; Li-Shu Wang; Benjamin W.S. Ransom; Steven G. Carmella; Chieh-Ti Kuo; Jibran Siddiqui; Jo-Hsin Chen; Kiyoko Oshima; Yi-Wen Huang; Stephen S. Hecht; Gary D. Stoner
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.